Yu Zhang

Yu Zhang

Auto-generated profile, based on publicly available information

Yu Zhang

Zheijang Clinovation Pride, Zhejiang, China; Deparment of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Zhejiang, China; Zhejiang Provincial Clinical Research Center for Digestive Diseases, Zhejiang, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
LYLingling Yan
Lingling Yan
RLRong Lin
Rong Lin
YZYu Zhang
Yu Zhang
SXShanjing Xu
Shanjing Xu
XZXianbin Zhou
Xianbin Zhou
LFLina Fang
Lina Fang
Background/Aims: Vonoprazan 20 mg twice daily is effective for Helicobacter pylori (H.pylori) eradication, but studies on the efficacy of 20 mg once daily are limited. The efficacy, tolerability, and cost-effectiveness of bismuth-based quadruple therapy with vonoprazan 20 mg once daily were evaluated for H. pylori eradication. Materials and Methods: A prospective cohort study was conducted at TaiZhou Hospital of Zhejiang Province between January and September 2024. Participants were divided into 2 groups: low-dose vonoprazan (QD, 20 mg once daily) and standard-dose vonoprazan (BID, 20 mg twice daily). The remaining drugs (colloidal bismuth pectin, clarithromycin, and amoxicillin) were the same for both groups, with a treatment duration of 14 days. Urea breath tests were performed 6-8 weeks post treatment. Results: In the intention-to-treat analysis, eradication rates were 89.2% (91/102) in the QD group and 88.9% (88/99) in the BID group, with no significant difference (P = .941). In the per-protocol (PP) analysis, eradication rates were 92.2% (83/90) in the QD group and 95.2% (79/83) in the BID group, also without a significant difference (P = .426). The incidence of adverse events was 8.9% in the QD group and 12.0% in the BID group (P = .497), respectively. The cost-effectiveness ratios were 2.59 for the QD group and 3.96 for the BID group in the PP analysis, respectively. Conclusion: Vonoprazan 20 mg once daily showed comparable efficacy to twice-daily dosing as part of a bismuth-based quadruple regimen for H. pylori eradication, with better cost-effectiveness, making it a promising option, especially in resource-limited settings. Cite this article as: Yan L, Lin R, Zhang Y, et al. Comparative effectiveness of vonoprazan dosing strategies in bismuth-based quadruple therapy for Helicobacter pylori eradication: A prospective non-inferiority cohort study. Turk J Gastroenterol. Published online February 13, 2026. doi: 10.5152/tjg.2026.25645.